utilisation of lung surfactant are likely to be of major importance in determining the fate of liposomes deposited in the alveoli. Administration of radiolabelled liposomes to the respiratory tract of rodents has shown that liposomal phospholipid rapidly becomes associated with the lung parenchyma.34 Exogenous phospholipids enter the process for reutilising lung surfactant, being taken up by type II epithelial cells, and become incorporated into lamellar bodies. 4 The rate and extent of pulmonary uptake of liposomes are a function of their composition, significantly faster rates occurring when liposomes contain phosphatidylglycerol. 3 A recent study of the acute effects of liposome inhalation by healthy volunteers indicated that small soya phosphatidylcholine liposomes were well tolerated, with no apparent changes in pulmonary function.5 Chronic administration of liposomes, however, may result in cumulative doses of phospholipid greater than the size of the lung surfactant pool. In clinical cases of phospholipidosis, occurring as an adverse reaction to amiodarone, concentrations of phospholipids in cell free bronchoalveolar lavage fluid remain normal but there is a large increase in the lavage cell population, predominantly of alveolar macrophages, and their phospholipid content.6 This suggests that macrophage activity may be an important clearance mechanism in response to chronic administration of liposomes.
Gamma scintigraphy has been used to study the deposition and clearance of radiolabelled liposomes in the human respiratory tract. These investigations have indicated that liposomes can be efficiently deposited in the lung, where they remain intact for prolonged periods. Whether they are deposited in the central or peripheral airways depends on the size of the droplets in the aerosols produced by nebulisers used for their delivery, rather than on properties of the vesicles themselves. The desired site of deposition within the lung will clearly be governed by the site of drug action. Rapid removal of particulates, including liposomes, by the mucociliary clearance process suggests that peripheral lung deposition will be required to achieve much longer drug action.
Multilamellar and small unilamellar liposomes with bilayers of dipalmitoylphosphatidylcholine, with a mean size of 2 9 gm and 70 nm respectively, had their outer surface labelled with 9"mTc before inhalation by healthy volunteers from a Hudson jet nebuliser. 7 The distribution of activity within the lung depended on the size of droplets in the nebulised aerosol cloud (mass median aerodynamic diameter (MMAD) 3 2-3-7 gm) rather than vesicle size or type. The rate of clearance of the two vesicle types was similar, with about 40% of deposited activity cleared within 20 hours by the mucociliary clearance process. The activity remaining in the lung after 20 hours probably represented vesicles that had been deposited in the alveoli.
Dipalmitoylphosphatidylcholine-cholesterol multilamellar liposomes (mean size 0 9 pm) with their aqueous phase labelled with 99mTc DTPA were atomised by a Respigard jet nebuliser (MMAD 12 pm)8 and inhaled by healthy volunteers. Such a small droplet size ensured peripheral lung deposition. Single photon emission computed tomography images one hour after inhalation showed that activity was widely distributed throughout the lungs. After 24 hours 45% of the initially deposited activity persisted within the lungs, representing the fraction of radiolabel remaining in intact liposomes in the alveolar regions, as free radiolabel was rapidly absorbed and cleared from the airways. When an equivalent dose of free 99mTc DTPA was inhaled as a solution, activity could not be detected in the pulmonary regions after six hours.
In the earliest studies of pulmonary administration of liposomes for therapeutic purposes liposomes were given as an exogenous lung surfactant in the treatment of the neonatal respiratory distress syndrome.9 Subsequently a range of liposome associated drugs have been administered to the lungs of humans and animals. These include cytotoxic drugs,'°a ntiasthma drugs," 12 antimicrobial compounds,'1-5 and drugs delivered for a systemic action. [1] [2] [3] [4] [5] [6] [7] When cytarabine was administered to the lungs of rabbits in free and liposomal form, the free drug was rapidly absorbed whereas the liposomal drug remained in the airways for prolonged periods, with little distribution to other tissues. Free cytarabine inhibited ['4C]thymidine incorporation in the gastrointestinal tract, bone marrow, and lung, whereas liposomal drug effectively inhibited
[I4C]thymidine incorporation within lung tissue but with little effect in the gastrointestinal tract and bone marrow.'0 Pulmonary administration of orciprenaline sulphate to guinea pigs produced bronchodilation of short duration accompanied by considerable tachycardia. Liposome for-mulations of that drug produced immediate bronchodilation after histamine induced bronchoconstriction, but with an appreciably prolonged duration of activity." Additionally, the cardiovascular side effects of orciprenaline were significantly reduced by liposomal incorporation.
Cytarabine and orciprenaline sulphate are hydrophilic drugs entrapped within the aqueous compartments of liposomes. Similar findings have been reported for hydrophobic drugs, such as atropine, associated with lipid bilayers.'7 These studies show the potential of liposomes for prolonging the time that drugs associated with them are retained in the lung, resulting in localised high drug concentrations within the respiratory tract and decreased adverse effects at sites distant from the lung.
Studies of inhaled liposomal drug formulations in man are scarce. Liposomes containing the antiviral compound enviroxime have been inhaled by healthy volunteers after atomisation from a Puritan-Bennett jet nebuliser producing aerosols with mass median diameters of 24-3-1 jYm.'4 From 7 to 10 mg of drug was deposited in the respiratory tract over one hour. Large amounts of drug were found in nasal washes one hour after inhalation. Enviroxime could not be detected in urine samples, and was detectable in only one of five blood samples. No side effects were observed and the authors concluded that such a liposome formulation had potential for delivering hydrophobic drugs for the treatment of respiratory disease. Nebulisation of free enviroxime is problematic owing to its poor solubility in water.
A Hudson jet nebuliser was used to produce aerosols Larger liposomes encapsulate more hydrophilic materials, but these vesicles are the least stable during atomisation. Reducing the size of liposomes by extrusion or sonication makes them more stable. Disruption ofvesicles on atomisation is likely to be less critical for hydrophobic drugs, associated as they are with lipid bilayers.
The use of ultrasonic nebulisers for liposome delivery has been investigated. 9 Small liposomes were stable during nebulisation, though dipalmitoylphosphatidylcholine vesicles of 500 nm or more increased in size within the nebuliser, suggesting fusion of vesicles, with the likely loss of entrapped hydrophilic materials.
In the future alternative devices may become available for delivery of liposomes to the lung. For instance, a recent United States patent20 described the use of a dry powder inhalation device for delivering vesicles loaded with spray dried drug. This approach to pulmonary delivery will rely on rehydration of vesicles in situ. The potential of metered dose inhalers has also been investigated. A solution phase system has been developed in which phospholipid and drug are dissolved in a chlorofluorocarbon based propellant blend.2' After inhalation of the emitted droplets it is postulated that rapid phospholipid hydration will result in spontaneous formation of vesicles. This approach has proved applicable for delivering systems containing small doses of salbutamol2' and would seem suitable for delivery of corticosteroids. Other approaches for metered dose inhaler systems include a two compartment system, in which a chlorofluorocarbon based solution containing phospholipid and drug is mixed with an aqueous phase on actuation,22 and a system in which preformed dehydrated liposomes are suspended in a chlorofluorocarbon blend with poor solubilising capacity for phospholipids.20 These alternative approaches are limited by the fact that smaller amounts of phospholipid or liposomes can be delivered than with nebulisers. From a toxicological viewpoint, then, liposomes seem particularly appropriate for drug delivery to the lung. The limited data pertaining to their use in man and the results of animal studies indicate that encapsulation in liposomes can modulate the fate of inhaled drugs, increasing the residence time of drug in the lung. This may allow prolonged drug action within the respiratory tract or a prolonged presence in the circulation. By providing a controlled delivery of drug at the surface of the lung such systems may allow a decreased frequency of dosing, with a reduction in systemic side effects. How controllable drug release from a liposome system deposited in the lung will be has yet to be established, in 
